Drug intelligence / Profile preview

Pearl-301

Development stage: Preclinical
Lead developer: PearlsInMires
Modality: Small Molecules

Overview

Pearl-301 is a preclinical-stage small molecule therapeutic being developed by the biotechnology company PearlsInMires for the treatment of alopecia. The drug is designed to target the androgen receptor (AR) and modulate the activity of dihydrotestosterone (DHT), a potent androgen that plays a central role in the pathogenesis of androgenetic alopecia by promoting hair follicle miniaturization. As of 2024, the program is in the preclinical phase of development, with the sponsor aiming to complete patent applications for the asset by 2025.

Other names: Pearl-301Pearl301Pearl 301

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on Pearl-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pearl-301.

Explore the full profile